Scarica l'app Stockscreener
181.55
1.81%
-3.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$184.90
Aprire:
$185.99
Volume 24 ore:
1.07M
Relative Volume:
0.65
Capitalizzazione di mercato:
$26.64B
Reddito:
$9.53B
Utile/perdita netta:
$1.29B
Rapporto P/E:
20.62
EPS:
8.8057
Flusso di cassa netto:
$1.97B
1 W Prestazione:
-1.80%
1M Prestazione:
-7.62%
6M Prestazione:
+25.33%
1 anno Prestazione:
+29.70%
Intervallo 1D:
$181.46
$188.00
Intervallo di 1 settimana:
$181.46
$192.99
Portata 52W:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
181.55 | 26.64B | 9.53B | 1.29B | 1.97B | 8.8057 |
|
LLY
Lilly Eli Co
|
985.08 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.90 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-09 | Reiterato | H.C. Wainwright | Buy |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Downgrade | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Aggiornamento | Stifel | Hold → Buy |
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Does New Once-Yearly SMA Data And Phase 3 Plan Change The Bull Case For Biogen (BIIB)? - simplywall.st
Biogen CLO Retiring After 20 Years With Biopharma Biz - Law360
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference - Yahoo Finance
Assessing Biogen (BIIB) Valuation After Recent Shareholder Return Momentum - simplywall.st
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Biogen’s Spinraza successor benefits SMA patients unresponsive to gene therapy - Yahoo
Swiss National Bank Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander Effective May 2026 - Minichart
Biogen presents Phase 1b data on salanersen for SMA treatment - Investing.com South Africa
Biogen Announces Upcoming Departure of Chief Legal Officer - TipRanks
Biogen chief legal officer Susan H. Alexander to depart at end of May - Investing.com
Oppenheimer reiterates Biogen stock rating on SMA drug data By Investing.com - Investing.com Nigeria
Oppenheimer reiterates Biogen stock rating on SMA drug data - Investing.com
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026 - marketscreener.com
Biogen Unveils Phase III Salanersen Program To Bring Longer-Acting SMA Option - Citeline News & Insights
Biogen builds case for Spinraza successor with fresh data - BioPharma Dive
To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? - Barchart.com
Biogen Settles Investors' $50M Claim Over Pain Drug Deal - Law360
Biogen presents additional salanersen data in SMA - The Pharmaletter
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock - Yahoo Finance
Biogen (BIIB) Reveals Promising Phase 1b Study Results for Salan - GuruFocus
Van ECK Associates Corp Has $149.46 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen presents new Phase 1b results for spinal muscular atrophy drug at MDA Conference - Traders Union
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy - Biogen
Biogen to Participate in the Stifel 2026 Virtual CNS Forum - Biogen
Therapeutics Sector Q4 2025 Earnings Review: Resilience and GrowthNews and Statistics - IndexBox
Causeway Capital Management LLC Acquires 74,163 Shares of Biogen Inc. $BIIB - MarketBeat
Jefferies Financial Group Inc. Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Down 36% intraday BIIB.SW Biogen Inc. (SIX) 09 Mar 2026: catalysts to track - Meyka
MDA 2026: Trio of trials now testing Spinraza successor salanersen for SMA - SMA News Today
Rhenman & Partners Asset Management AB Boosts Biogen Stake by 358% - National Today
Rhenman & Partners Asset Management AB Has $7.70 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen’s Dravet And SMA Advances Add Depth To Long Term Story - simplywall.st
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts - MarketBeat
Biogen Inc (BIIB) Shares Gap Down to $181.74 on Mar 6 - GuruFocus
Health Rounds: Protein related to Parkinson's linked to faster Alzheimer's progression in women - marketscreener.com
Biogen/Stoke’s zorevunersen hailed as potential first disease-modifying drug for rare epilepsy - European Pharmaceutical Review
Spinal muscular atrophy research progresses at 2026 MDA Conference, Biogen asserts - Traders Union
What Makes Biogen (BIIB) an Attractive Long-Term Holding? - Insider Monkey
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences - Biogen
Biogen Inc Announces to Present New Data and Updates from Its Spinal Muscle Atrophy Research Programs - marketscreener.com
(BIIB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Mo - PharmiWeb.com
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - Biogen
Elo Mutual Pension Insurance Co Boosts Biogen Stake - National Today
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):